Renhuang Pharmaceuticals Rated ‘Outperform’ Target Price $7.00 by Beacon Equity Research
Written by BUSINESS WIRE
Nov 15, 2007 at 05:50 PM
DALLAS--(BUSINESS WIRE)--Renhuang Pharmaceuticals (OTCBB:RHGP) has been rated Outperform with a price target of $7.00 by Beacon Equity Research Analyst, Lisa Springer, CFA.
Anyone interested in receiving alerts regarding Renhuang Pharmaceuticals research should email with “RHGP” in the subject line.
In the report, the analyst writes, “Renhuang Pharmaceuticals manufactures and distributes a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products in mainland China. Its three major product lines are Acanthopanax-based natural medicinal products, the Shark Power healthcare series and traditional Chinese medicines.
“Renhuang has established a multi-channel research and development infrastructure consisting of in-house researchers, a post-doctoral working center, and collaborations with leading institutions and scientists. The Company has a portfolio of over 100 products, and a presence in more than 50 markets. It has a dominant share of the market for Acanthopanax-based natural medicines and controls 70% of China's Acanthopanax resource (also known as Siberian Ginseng). Products are distributed through a network of over 2,000 sales agents in 24 districts covering over 50% of China and also exported to Russia and Southeast Asia.”
Other companies in the pharmaceutical sector include American Oriental Bioengineering (NYSE:AOB), 3SBio Inc. (NASDAQ:SSRX), Benda Pharmaceuticals (OTCBB:BPMA), and Sinobiomed (OTCBB:SOBM).
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of Renhuang Pharmaceuticals (RHGP). Additionally the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research (“Beacon”) certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon Equity Research and its affiliates have been directly compensated a total of ten thousand restricted rule 144 shares from Viking Investments for enrollment of RHGP in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.
Contacts Beacon Equity Research Jeff Bishop, 469-361-6239 www.BeaconEquityResearch.com or Renhuang Pharmaceuticals, Inc. Ms. Gina Gao, 86-451-5762-0378 Fax: 86-451-5762-0378 Web: www.renhuang.com Email:
China Pharma News 